All News

The FDA approved Tylenol with Naproxen, the first OTC fixed-dose combination of acetaminophen and naproxen sodium, for up to 12 hours of relief from minor aches and pains in patients 12 years and older.

This week's episode covers a new AHA scientific statement on caffeine safety and cardiovascular benefit; pharmacist guidance for protecting patients with asthma, COPD, and allergies during wildfire smoke events; and regulatory updates in obstructive sleep apnea and ROS1-positive lung cancer.

Data show adalimumab biosimilars can replace brand-name treatment with minimal gaps, high persistence, and sharply lower drug costs for patients and plans.

A yearlong trial suggests the tuberculosis vaccine may retrain immune cells in the brain and shift Alzheimer-related biomarkers in older adults without existing pathology.

In an interview with Pharmacy Times, Erin J. Walsh, PharmD, MS, RPh, MCST, discusses where VER-01 could fit in chronic pain management and why advances in standardized cannabinoid therapies may represent a pivotal moment for the future of evidence-based cannabis-derived medicines.

Jordan Hill, PharmD, BCOP, discusses the expanded first-line role of sacituzumab govitecan in metastatic triple-negative breast cancer and how PD-L1 status informs its use alone or with pembrolizumab.

Federal guidelines and clinical evidence suggest that doubling or even tripling up on shots is not only safe but is also a best practice.

In an interview with Pharmacy Times, Erin J. Walsh, PharmD, MS, RPh, discusses what the phase 3 data reveal about VER-01's potential and explains how pharmacists could help integrate standardized cannabinoid therapies into evidence-based chronic pain management.

Five consistent habits—not stock-picking or complex strategies—separate pharmacists who quietly build multi-million-dollar net worths from those who don't.

Although weight loss is a primary goal, the ultimate utility of these agents lies in their ability to reduce long-term morbidity.

Holistic, integrative, functional, precision—the labels are everywhere, but few patients or clinicians know where one ends and the next begins.

Flu vaccine rates are lagging as hesitancy rises, but community pharmacists boost vaccination with trusted counseling, easy access, and outreach.

SHASTA-3 and SHASTA-4 also showed a statistically significant drop in acute pancreatitis events, supporting a planned US sNDA this year.

The first 2 weeks have produced a specific, recurring set of counter-level problems that have nothing to do with clinical appropriateness.

Oncology pharmacy teams can integrate newly approved breast cancer therapies into practice while addressing operational barriers, monitoring requirements, and financial toxicity.

Cassandra Perkey, PharmD, BCOP, explains the operational, staffing, infrastructure, safety, and pharmacist-led requirements for successfully delivering CAR T-cell therapy in a community oncology setting.

In an interview with Pharmacy Times, Erin J. Walsh, PharmD, MS, RPh, explains how VER-01 differs from dispensary cannabis products, emphasizing the importance of pharmaceutical standardization, consistent dosing, and rigorous clinical evaluation.

NHANES data from 1999 to 2023 show obesity, severe obesity, and abdominal obesity climbing across all age groups, with pharmacists positioned to intervene.

GSK's next-generation ROS1 inhibitor earns approval after demonstrating durable responses in the ARROS-1 trial, including among patients with brain metastases.

In an interview with Pharmacy Times, Erin J. Walsh, PharmD, MS, RPh, discusses what sets VER-01 apart from previous cannabis-derived therapies, why it has generated significant interest in chronic pain research, and how its standardized pharmaceutical approach could shape the future of evidence-based pain management.

Cassandra Perkey, PharmD, BCOP, discusses how pharmacists support community CAR T-cell programs through SOP development, treatment planning, education, emergency preparedness, and lessons learned from treating the first patient.

Australian trial shows bivalent mRNA COVID-19 booster lifts antibodies more than protein vaccine, yet both cut infection similarly over 12 months.

Adding palbociclib to anti-HER2 and endocrine maintenance therapy provides a new treatment option for patients with HR-positive, HER2-positive metastatic breast cancer.

The pharmacist’s role is transforming from product management to clinical specialization.

A global trial found the long-acting analogue reduced severe hypoglycemia and nighttime lows in youth with type 1 diabetes by 12 months, not 6.

As 2026 wildfire smoke from Canada blankets the US, pharmacists can facilitate early refills, counsel on protective measures, and help patients understand when worsening symptoms require emergency care.

New scientific statement links moderate caffeine to lower cardiovascular risk—but flags energy drinks as a distinct hazard pharmacists should counsel on.

Robert J. DiDomenico, PharmD, FAHA, discusses the new AHA scientific statement on identifying and safely deprescribing unnecessary medications in patients with cardiovascular disease.